Five-year follow-up of ibrutinib plus rituximab vs placebo plus rituximab for Waldenström's macroglobulinemia: Final analysis from the randomized phase 3 iNNOVATE™ study Meeting Abstract
| Authors: | Buske, C.; Tedeschi, A.; Trotman, J.; García-Sanz, R.; MacDonald, D.; Leblond, V.; Mahé, B.; Herbaux, C.; Matous, J. V.; Tam, C. S.; Heffner, L. T.; Varettoni, M.; Lia Palomba, M.; Shustik, C.; Kastritis, E.; Treon, S. P.; Ping, J.; Hauns, B.; Arango-Hisijara, I.; Dimopoulos, M. A. |
| Abstract Title: | Five-year follow-up of ibrutinib plus rituximab vs placebo plus rituximab for Waldenström's macroglobulinemia: Final analysis from the randomized phase 3 iNNOVATE™ study |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607205605068 |
| DOI: | 10.1182/blood-2020-134460 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 24 -- Source: Wos |
